Based on the observation that resistance to HER2‐targeted therapies in breast cancer is sometimes associated with an increased expression of epidermal growth factor receptors (EGFR), Reilly's group developed a radiation nanomedicine targeting the two receptors that was evaluated in vitro.[32]177Lu‐Au nanoparticles were grafted both with trastuzumab (to target HER2) and panitumumab (to target EGFR), and the nanohybrids were studied in interaction with breast cancer cells overexpressing either HER2, EGFR, or both receptors. Here, ERBB2 is linked to breast carcinoma.